US20230330154A1

US20230330154A1 - Methods of treating systemic graft- versus-host disease with extracellular vesicles

Info

Publication number: US20230330154A1
Application number: US17/983,797
Authority: US
Inventors: Luis RODRIGUEZ-BORLADO; Houman Hemmati; Kiel A. Peck; Linda Marban; Jennifer J. MOSELEY
Original assignee: Capricor Inc
Current assignee: Capricor Inc
Priority date: 2017-05-05
Filing date: 2022-11-09
Publication date: 2023-10-19
Also published as: US20200054686A1; WO2018204889A1; JP7360704B2; EP3600151A4; JP2020518564A; US11529376B2; EP3600151A1

Abstract

The present invention relates to a method of treating acute or chronic systemic graft-versus-host disease (GVHD) with extracellular vesicles, e.g., exosomes obtained from human cardiospheres or cardiosphere-derived cells (CDCs), wherein systemic GVHD involves, e.g., at least two organs selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, genitalia, and eyes. The present invention also provides a pharmaceutical formulation comprising extracellular vesicles, e.g., exosomes obtained from human cardiospheres or CDCs, for systemic administration, e.g., intravenous infusion, to a human subject in need of treatment of systemic GVHD.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/610,859, which is a U.S. national stage filing of International Patent Application No. PCT/US2018/031257, which was filed on May 4, 2018, and which claims priority to U.S. Provisional Application No. 62/506,880, which was filed on May 16, 2017, and U.S. Provisional Application No. 62/502,474, which was filed on May 4, 2017, all of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Graft-versus-host disease (GVHD) occurs when cells transplanted from a non-identical donor (typically bone marrow, T-cell, and/or hematopoietic stem cell donor; the graft) recognize and mount a deleterious immune response against antigens found in the transplant recipient (the host). See, e.g., Billingham, “The Biology of Graft-Versus-Host Reactions,” Harvey Led, 62:2-1% (1966-1967). The disease presents as a heterogeneous condition involving multiple organs, most commonly the skin, mucosa, gastrointestinal tract, liver and lungs. For patients undergoing allogeneic hematopoietic stem cell transplant (HSCT), GVHD is a significant cause of morbidity and mortality. Due to the large number of variables affecting disease risk, there is a wide range of incidence reported for both acute and chronic GVHD. Up to 80% of patients will develop GVHD at approximately 14-21 days following HSCT (acute), and of those surviving beyond 100 days, between 30 and 70% will develop chronic GVHD. Unsurprisingly, chronic GVHD represents the single leading cause of death in HSCT survivors. See, e.g., Pasquini et al, “2010 Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): Current Uses and Outcomes of Hematopoietic Cell Transplants for Blood and Bone Marrow Disorders,” Clin Transpl, 87-105 (2010).
Development of GVHD is dependent on the activation of antigen-specific donor T cells that are able to mount a specific immune response targeting host tissues. This event is potentiated by conditioning of the host prior to HSCT in order to suppress the immune system and ensure effective engraftment. Host tissue damage is mediated by cytotoxic T cells involving a variety of mechanisms, including direct cell contact and the production of soluble pro-inflammatory mediators. See, e.g., Ferrara et al, “Graft-Versus-Host Disease,” Lancet, 373: 1550-1561 (2009); Sakoda et al, “Donor-Derived Thymic-Dependent T Cells Cause Chronic Graft-Versus-Host Disease,” Blood, 109: 1756-1764 (2010). Multiple T-helper cell subsets have been shown to be involved, including Thl, Th2, and Thl7. See, e.g., Broady et al, “Cutaneous GVHD is Associated with the Expansion of Tissue-Localized Thl and not Th17 Cells,” Blood, 116:5749-5751 (2010); Murphy et al, “Differential Effects of the Absence of Interferon-Gamma and IL-4 in Acute Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation in Mice,” J Clin Invest, 102: 1742-1748 (1998); Nikolic et al., “Th1 and Th2 Mediate Acute Graft-Versus-Host Disease, each with Distinct End-Organ Targets,” J Clin Invest., 105: 1289-1298 (2000). The current understanding of their specific roles is complex: in some models, Thl7 cells have been shown to be sufficient for induction of GVHD, whereas in others their absence has been shown to exacerbate disease. See, e.g., Yi et al, “Absence of Donor Th1 7 Leads to Augmented Th1 Differentiation and Exacerbated Acute-Graft-Versus-Host Disease,” Blood, 112:2101-2110 (2008); Kappel et al, “IL-17 Contributes to CD4-Mediated Graft-Versus-Host Disease,” Blood, 113:945-952 (2009).
Despite the advances in understanding the immuno-pathological basis of the disease and associated risk factors, and the development of more effective MHC matching and immune conditioning, little progress has been made in decreasing late transplantation-related mortality. The focus of current therapy is general immune suppression using corticosteroids, which has dubious efficacy; sustained amelioration of disease symptoms are only seen in around 50% of patients. See, e.g., Billingham, “The Biology of Graft-Versus-Host Reactions,” Harvey Lect., 62:2-1% (1966-1967). More promising therapies are based on the prophylactic prevention of GVHD, and use T cell targeting agents such as methotrexate and tacrolimus. This lack of success is mainly the result of the failure to reduce the incidence and severity of chronic GVHD.
Cells release into the extracellular environment diverse types of membrane vesicles of endosomal and plasma membrane origin called exosomes and microvesicles, respectively. These extracellular vesicles represent an important mode of intercellular communication by serving as vehicles for transfer between cells of membrane and cytosolic proteins, lipids, and RNA. See, e.g., Graca Raposo and Willem Stoorvogel, “Extracellular Vesicles: Exosomes, Microvesicles, and Friends,” The Journal of Cell Biology, Vol. 200, No. 4, 373-383 (2013). WO 2014/028493 describes exosomes derived from cardiosphere-derived cells (CDCs) and their therapeutic utility for the repair or regeneration of damaged or diseased cells or tissue, e.g., damaged cardiac tissue. US 2012/0315252 describes CDCs, their derivation from cardiospheres, and their therapeutic utility for increasing the function of a damaged or diseased heart of a mammal. WO 2005/012510 describes cardiospheres, their derivation from human or animal cardiac tissue biopsy samples, and their therapeutic utility in cell transplantation and functional repair of the myocardium or other organs.

SUMMARY OF THE INVENTION

The present invention is based on the surprising discovery by the present inventors that extracellular vesicles, in particular exosomes derived from cardiosphere-derived cells (CDCs), have immunomodulatory capabilities on T cells and are effective in treating systemic graft-versus-host disease (GVHD), as demonstrated for the first time in a relevant mouse model of systemic GVHD. The advantage of the method of the present invention as described herein is that it is a safe, systemically-administered biologic therapy that can improve both survival and end-organ damage (e.g., gastrointestinal tract and eyes) in GVHD by modulating the immune response and reducing inflammation and fibrosis. This causes reduction in end-organ morbidities such as ocular GVHD and weight loss attributable to poor nutrient absorption in the gastrointestinal tract, leading to inter alia improved survival and presumably enhanced quality of life.
For the purpose of the present invention, the term “systemic GVHD” is used interchangeably with “GVHD”, and refers to acute or chronic GVHD requiring or amenable to treatment by systemic administration of extracellular vesicles, e.g. exosomes and/or microvesicles, derived from CDCs.
Generally, the present invention provides a method of safely treating systemic GVHD in a subject in need thereof, the method comprising systemically administrating to the subject a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs, wherein systemic GVHD is a syndrome involving multiple organs, most commonly the skin, mucosa, gastrointestinal tract, liver, and lungs, wherein cells originating from a donor (typically bone marrow, T-cell, and/or hematopoietic stem cell donor) recognize and mount a deleterious immune response against antigens found in the immunocompromised recipient.
According to one aspect of the present invention, systemic administration of a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs, results in treatment of systemic GVHD with respect to at least one organ selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, and lungs. Alternatively, according to the present invention, said administration of a therapeutically effective amount of extracellular vesicles results in treatment of systemic GVHD with respect to at least two organs selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, and lungs.
According to another aspect of the present invention, systemic administration of a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs, results in treatment of systemic GVHD with respect to at least one organ selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, and genitalia. Alternatively, according to the present invention, said administration of a therapeutically effective amount of extracellular vesicles results in treatment of systemic GVHD with respect to at least two organs selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, and genitalia.
According to another aspect of the present invention, systemic administration of a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs, results in treatment of systemic GVHD with respect to at least one organ selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, and genitalia, and the eyes.
According to another aspect of the present invention, systemic administration of a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs, results in treatment of systemic GVHD with respect to the eyes.
According to the present invention, a therapeutically effective amount of extracellular vesicles, e.g., exosomes and/or microvesicles, derived from CDCs, is systemically administered one or more times after the subject has undergone HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject less than, e.g., 1 hour post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject less than, e.g., 1-24 hours post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject less than, e.g., 24-48 hours post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject, e.g., 1-2 weeks post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject, e.g., 2-3 weeks after post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject, e.g., 4-8 weeks post HSCT. In some embodiments, a therapeutically effective amount of extracellular vesicles is systemically administered to the subject, e.g., 1, 2, 3, 4, 5, 6, 7, and/or 8 weeks after HSCT, one or more times, e.g., 7 days apart between successive administrations.
According to the present invention, said subject is a mammal, e.g., a human; said systemic administration is via, e.g., intra-vascular administration, intraventricular administration, intrathecal administration, or intraperitoneal administration, wherein said intra-vascular administration is, e.g., intravenous, intra-arterial, or intracoronary infusion or injection.
According to the present invention, said extracellular vesicles are exosomes, microvesicles, membrane particles, membrane vesicles, exosome-like vesicles, ectosomes, ectosome-like vesicles, exovesicles, epididimosomes, argosomes, promininosomes, prostasomes, dexosomes, texosomes, archeosomes, oncosomes, or the like.
According to an embodiment of the present invention, said extracellular vesicles are derived from CDCs cultured in serum-free medium (e.g., IMDM) and incubated at about 5% O2 for about 15 days, wherein said extracellular vesicles are obtained after filtering CDC condition medium containing extracellular vesicles through a 1000 kDa pore sized filter. More generally, according to the present invention, said extracellular vesicles are derived from CDCs cultured in serum-containing or serum-free medium and incubated at 2-20% O2 for 1-15 days, wherein said extracellular vesicles are obtained after filtering CDC condition medium containing extracellular vesicles through a 3-1000 kDa (e.g., 10 kDa) pore sized filter. Alternatively, extracellular vesicles are obtained by precipitation with polyethylene glycol (e.g., 25% PEG).
According to the present invention, extracellular vesicles, e.g., exosomes, are formulated in a crystalloid solution (e.g., Plasmalyte, normal saline), aqueous solution, gel, ointment, cream, topical or implantable hydrogel, powder, sustained-release polymer (e.g., PLGA and PLA), polyethylene glycol (PEG)-containing solution, suspension, emulsion, as part of a drug delivery device, insert, patch, or the like. In several embodiments, prior to use, extracellular vesicles, e.g., exosomes, are resuspended in an appropriate buffer, e.g., sterile PBS with or without human serum albumin. In some embodiments, exosomes can be stored for future use, e.g., frozen at −80° C.
In several embodiments, extracellular vesicles, e.g., exosomes, are derived from human or animal cells. In several embodiments, extracellular vesicles, e.g., exosomes, are prepared from cardiospheres or CDCs. In some embodiments, extracellular vesicles, e.g., exosomes, are prepared from regenerative stem cells such as embryonic stem cells, pluripotent stem cells, multipotent stem cells, induced pluripotent stem cells, post-natal stem cells, adult stem cells, mesenchymal stem cells, hematopoietic stem cells, endothelial stem cells, epithelial stem cells, neural stem cells, cardiac stem cells including cardiac progenitor cells, bone marrow-derived stem cells, adipose-derived stem cells, hepatic stem cells, peripheral blood derived stem cells, cord blood-derived stem cells, placental stem cells, or the like.
In several embodiments, extracellular vesicles, e.g., exosomes, are modified (e.g., genetically or otherwise) to direct them to a specific target site. For example, a modification may, in some embodiments, comprise inducing expression of a specific cell-surface marker on the exosome, which results in specific interaction with a receptor on a desired target tissue. In one embodiment, the native contents of the exosome are removed and replaced with, or supplemented with, desired exogenous proteins and/or nucleic acids.
In several embodiments, extracellular vesicles, e.g., exosomes, include one or more microRNAs selected from: miR-146a, miR-148a, miR-22, miR-24, miR-210, miR-150, miR-140-3p, miR-19a, miR-27b, miR-19b, miR-27a, miR-376c, miR-128, miR-320a, miR-143, miR-21, miR-130a, miR-9, miR-185, and miR-23a. In a preferred embodiment, extracellular vesicles, e.g., exosomes, comprise miR-146a and miR-210. In several embodiments, extracellular vesicles, e.g., exosomes, include one or more microRNAs selected from: hsa-miR-23α-3p, hsa-miR-130a-3p, hsa-miR-21-5p, hsa-miR-4516, hsa-let-7a-5p, hsa-miR-125b-5p, hsa-miR-199a-3p, hsa-miR-199b-3p, hsa-miR-22-3p, hsa-miR-24-3p, hsa-miR-1290, hsa-miR-320e, hsa-miR-423-5p, hsa-miR-22-3p, hsa-miR-222-3p (also known as miR-221-3p), hsa-miR-100-5p, hsa-miR-337-5p, hsa-miR-27b-3p, hsa-miR-1915-3p, and hsa-miR-29b-3p, hsa-miR-25-3p (also known as miR-92a-3p).
In several embodiments, extracellular vesicles, e.g., exosomes, contain biological proteins, e.g., transcription factors, cytokines, growth factors, and similar proteins capable of modulating signaling pathways in a target cell. In some embodiments, the biological protein is capable of facilitating regeneration and/or improved function of a tissue. In some embodiments, the biological protein is capable of modulating pathways related to Irak1, Traf6, toll-like receptor (TLR) signaling pathway, NOX-4, SMAD-4, and/or TGF-β. In some embodiments, the biological protein is related to exosome formation and packaging of cytosolic proteins such as Hsp70, Hsp90, 14-3-3 epsilon, PKM2, GW182 and AG02. In some embodiments, extracellular vesicles, e.g., exosomes, contain signaling lipids, e.g., ceramide and derivatives.
In several embodiments, extracellular vesicles, e.g., exosomes, express tetraspanins, e.g., CD63, CD81, CD82, CD53, and/or CD37. In some embodiments, extracellular vesicles, e.g., exosomes, express one or more lipid raft associated proteins (e.g., glycosylphosphatidylinositol-anchored proteins and flotillin), cholesterol, sphingomyelin, and/or hexosylceramides.
In several embodiments, extracellular vesicles, e.g., exosomes, have a diameter of, e.g., about 15-250 nm, about 15-205 nm, about 90-220 nm, about 30-200 nm, about 20-150 nm, about 70-150 nm, or about 40-100 nm. In several embodiments, extracellular vesicles, e.g., microvesicles, have a diameter of, e.g., about 100-1000 nm.
In several embodiments, extracellular vesicles, e.g., exosomes, are purified such that contaminants or undesired compounds are removed from the exosomes. In some embodiments, the patient is administered substantially purified exosomes such that about 50% to 90%, or up to 100%), of the contaminants are removed from the exosomes. In some embodiments, an exosome preparation is essentially free of non-exosome components.
In several embodiments, extracellular vesicles, e.g., exosomes, are administered in combination with one or more additional agents. For example, in several embodiments, the exosomes are administered in combination with one or more proteins or nucleic acids derived from the exosome. In several embodiments, the cells from which the exosomes are isolated are administered in conjunction with the exosomes. In several embodiments, such an approach advantageously provides an acute and more prolonged duration of exosome delivery (e.g., acute based on the actual exosome delivery and prolonged based on the cellular delivery, the cells continuing to secrete exosomes post-delivery).
In several embodiments, the dose of extracellular vesicles, e.g., exosomes ranges about 1.0×10⁵to about 1.0×10¹⁰exosomes. In certain embodiments, the exosome dose is administered on a per kilogram basis, e.g., about 1.0×10⁵exosomes/kg to about 1.0×10⁹exosomes/kg. In additional embodiments, exosomes are delivered in an amount based on the mass of the target tissue, e.g., about 1.0×10⁵exosomes/gram of target tissue to about 1.0×10⁹exosomes/gram of target tissue. In several embodiments, exosomes are administered based on a ratio of the number of exosomes to the number of cells in a particular target tissue. If exosomes are to be administered in conjunction with the concurrent therapy (e.g., cells that can still shed exosomes, pharmaceutical therapy, nucleic acid therapy, and the like) the dose of exosomes administered can be adjusted accordingly (e.g., increased or decreased as needed to achieve the desired therapeutic effect).
The present invention further provides a formulation comprising extracellular vesicles for use in the treatment of systemic GVHD according to the aforementioned method.
The present invention further provides a use of the aforementioned formulation for treating systemic GVHD according to the aforementioned method.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a diagram showing how systemic GVHD is induced in BALB/c mice.

FIG. 2A is a photograph showing an example of Grade 0 for the posture criterion of the GVHD score.

FIG. 2B is a photograph showing an example of Grade 1 for the posture criterion of the GVHD score.

FIG. 2C is a photograph showing an example of Grade 2 for the posture criterion of the GVHD score.

FIG. 3 A is a photograph showing an example of Grade 0 for the fur texture criterion of the GVHD score.

FIG. 3B is a photograph showing an example of Grade 1 for the fur texture criterion of the GVHD score.

FIG. 3C is a photograph showing an example of Grade 2 for the fur texture criterion of the GVHD score.

FIG. 4A is a photograph showing an example of Grade 0 for the skin integrity criterion of the GVHD score.

FIG. 4B is a photograph showing an example of Grade 1 for the skin integrity criterion of the GVHD score.

FIG. 4C is a photograph showing an example of Grade 2 for the skin integrity criterion of the GVHD score.

FIG. 5 schematically illustrates the study design for evaluating the efficacy of extracellular vesicles to treat systemic GVHD.

FIG. 6A graphically shows the effects of intravenous administration of extracellular vesicles on the weight of the mouse model of systemic GVHD.

FIG. 6B shows the same data of FIG. 6A as AUC to enable effective comparison of groups by statistical test.

FIG. 7A graphically shows the effects of intravenous administration of extracellular vesicles on the overall GVHD score.

FIG. 7B shows the same data of FIG. 7A as AUC to enable effective comparison of groups by statistical test.

FIG. 8A graphically shows the effects of intravenous administration of extracellular vesicles on the posture criterion of the GVHD score.

FIG. 8B graphically shows the effects of intravenous administration of extracellular vesicles on the activity criterion of the GVHD score.

FIG. 8C graphically shows the effects of intravenous administration of extracellular vesicles on the fur activity criterion of the GVHD score.

FIG. 8D graphically shows the effects of intravenous administration of extracellular vesicles on the skin integrity criterion of the GVHD score.

FIG. 9 graphically shows the effects of intravenous administration of extracellular vesicles on the survival of the mouse model of systemic GVHD.

FIGS. 10A-B graphically show the effects of intravenous administration of extracellular vesicles on the diarrhea incidence of the mouse model of systemic GVHD.

FIGS. 11A-C graphically show the effects of intravenous administration of extracellular vesicles on the eye inflammation of the mouse model of systemic GVHD.

FIG. 12 graphically shows the effects of intravenous administration of extracellular vesicles on the colitis scores of the mouse model of systemic GVHD.

FIG. 13 graphically shows the same data as in FIG. 12 as sum colitis scores.

FIG. 14 graphically shows the effects of intravenous administration of extracellular vesicles on the colon histopathology severity scores of the mouse model of systemic GVHD.

FIG. 15 graphically shows the effects of intravenous administration of extracellular vesicles on the eye average histopathology scores of the mouse model of systemic GVHD.

FIG. 16 is a western blot showing CDC-EVs' contents of recognized exosomes markers.

FIG. 17 graphically shows the expression of immune molecules involved in T and natural killer (NK) immune response on CDC-EVs.

FIG. 18 . Shows in vitro update of CDC-EVs in Jurkat T cells.

FIG. 19 shows the immune modulation of PHA-induced T cells proliferation by and CDC-EVs.

FIG. 20 graphically shows the down-regulation of PHA-induced CD69 and/or HLA-DR expression by CDCs and CDC-EVs.

FIG. 21 graphically shows that CDC-EVs down regulate PHA-induced T cells

proliferation.

FIG. 22 graphically shows that immune modulation of PHA-induced CD4+ and CD8+ T cells proliferation by CDC-EVs.

DETAILED DESCRIPTION OF THE INVENTION

A) Clinical Manifestations

GVHD has been classically divided into acute and chronic variants based upon the time of onset using a cutoff of 100 days. Clinical manifestations of chronic GVHD include skin involvement resembling lichen planus or the cutaneous manifestations of scleroderma, dry oral mucosa with ulcerations and sclerosis of the gastrointestinal tract, and a rising serum bilirubin concentration. In contrast, patients with acute GVHD commonly demonstrate a classic maculopapular rash, abdominal cramps with diarrhea, and a rising serum bilirubin concentration. However, this conventional division has been challenged by the recognition that signs of acute and chronic GVHD may occur outside of these designated periods. This observation has led to the increased use of clinical findings, rather than a set time period, to differentiate between acute and chronic GVHD. The widely accepted National Institutes of Health (NIH) consensus criteria for the diagnosis of GVHD include an overlap syndrome in which diagnostic or distinctive features of chronic GVHD and acute GVHD appear together. See, e.g., Filipovich et al., “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: I. Diagnosis and Staging Working Group Report,” Biol
Blood Marrow Transplant, 11(12):945 (2005).
The NIH consensus criteria for identifying signs and symptoms of chronic GVHD are summarized in Table 1. See, e.g., Jagasia et al., “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report,” Biol Blood Marrow Transplant, 21:389 (2015).

TABLE 1

Mouth:	Mild symptoms with	Moderate symptoms	Severe symptoms with
Lichen planus-like	disease signs but not	with disease signs with	disease signs on
features	limiting oral intake	partial limitation of	examination with
	significantly	oral intake	major limitation of oral
			intake
Gastrointestinal Tract:	Symptoms without	Symptoms associated	Symptoms associated
Esophageal web/proximal	significant weight loss	with mild to moderate	with significant weight
stricture or ring;	(<5%)	weight loss (5-15%), or	loss(>15%); requires
dysphagia; anorexia;		moderate diarrhea	nutritional supplement
nausea; vomiting;		without significant	for most calorie needs,
diarrhea; weight loss;		interference with daily	or esophageal dilation,
failure to thrive		living	or severe diarrhea with
			significant interference
			with daily living
Liver	Normal total bilirubin	Elevated total bilirubin	Elevated total bilirubin
	with alanine	but 3 mg/dL, or	but >3 mg/dL
	aminotransferase	ALT > 5ULN
	(ALT) 3-5 × upper
	limit of normal (ULN),
	or alkaline phosphatase
	(AP) 3 × ULN
Lungs:	Mild symptoms	Moderate symptoms	Severe symptoms
Pulmonary function tests	(shortness of breath	(shortness of breath	(shortness of breath at
	after climbing one	after walking on flat	rest; requiring 02);
	flight of steps);	ground); FEV1 = 40-	FEV1 39%
	forced expiratory	59%
	volume in 1 second
	(FEV1) 60-79%
Joints and Fascia	Mild tightness of arms	Tightness of arms or	Contractures with
	or legs, normal or mild	legs, or joint	significant decrease of
	decreased range of	contractures, erythema	ROM, and significant
	motion (ROM), and	thought due to fasciitis,	limitation of ADL
	not affecting ADL	decreased ROM, and	(unable to tie shoes,
		mild to moderate	button shirts, dress self,
		limitation of ADL	etc.)
Genital Tract	Mild signs and females	Moderate signs and	Severe signs with or
	with or without	may have symptoms	without symptoms
	discomfort on exam	with discomfort on
		exam
Eyes:	Mild dry eye	Moderate dry eye	Severe dry eye
Keratoconjunctivitis sicca	symptoms not affecting	symptoms partially	symptoms significantly
(KCS) confirmed by	activities of daily	affecting ADL;	affecting ADL;
ophthalmologist	living (ADL);	requiring lubricant eye	Special eyeware to
	requiring lubricant eye	drops >3 × per day or	relieve pain, or unable
	drops
3 × per day	punctal plugs; without	to work because of
		new vision impairment	ocular symptoms, or
		due to KCS	loss of vision due to
			KCS

Patients diagnosed with chronic GVHD are then subclassified based upon the presence or absence of features of acute GVHD into one of two categories: (i) classic chronic GV.HD: Features of chronic GVH-D are present without signs or symptoms of acute GVH-D; (ii) overlap syndrome: Features of both chronic GVHD and acute GVHD are present.
Features of acute GVHD seen in the overlap syndrome include changes in the skin (skin erythema, maculopapular rash, pruritus), mouth (gingivitis, mucositis, oral erythema, oral pain), gastrointestinal symptoms (anorexia, nausea, vomiting, diarrhea, weight loss, failure to thrive), liver dysfunction (elevations in bilirubin, alkaline phosphatase, ALT, or AST), and organizing pneumonia (also called bronchiolitis obliterans organizing pneumonia).
For the purpose of the present invention, terms such as “treating” and “treatment” as used herein refer to therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed pathologic condition or disorder. For instance, a subject is successfully “treated” according to the methods of the present invention if the subject shows clinical improvement according to the NIH consensus criteria for identifying signs and symptoms of chronic GVHD.

B) Cardiospheres

Cardiospheres are undifferentiated cardiac cells that grow as self-adherent clusters as described in WO 2005/012510, and Messina et al, “Isolation and Expansion of Adult Cardiac Stem Cells From Human and Murine Heart,” Circulation Research, 95: 911-921 (2004), the disclosures of which are herein incorporated by reference in their entirety.
Briefly, heart tissue can be collected from a patient during surgery or cardiac biopsy. The heart tissue can be harvested from the left ventricle, right ventricle, septum, left atrium, right atrium, crista terminalis, right ventricular endocardium, septal or ventricle wall, atrial appendages, or combinations thereof. A biopsy can be obtained, e.g., by using a percutaneous bioptome as described in, e.g., U.S. Patent Application Publication Nos. 2009/012422 and 2012/0039857, the disclosures of which are herein incorporated by reference in their entirety. The tissue can then be cultured directly, or alternatively, the heart tissue can be frozen, thawed, and then cultured. The tissue can be digested with protease enzymes such as collagenase, trypsin and the like. The heart tissue can be cultured as an explant such that cells including fibroblast-like cells and cardiosphere-forming cells grow out from the explant. In some instances, an explant is cultured on a culture vessel coated with one or more components of the extracellular matrix (e.g., fibronectin, laminin, collagen, elastin, or other extracellular matrix proteins). The tissue explant can be cultured for about 1, 2, 3, 4, or more weeks prior to collecting the cardiosphere-forming cells. A layer of fibroblast-like cells can grow from the explant onto which cardiosphere-forming cells appear. Cardiosphere-forming cells can appear as small, round, phase-bright cells under phase contrast microscopy. Cells surrounding the explant including cardiosphere-forming cells can be collected by manual methods or by enzymatic digestion. The collected cardiosphere-forming cells can be cultured under conditions to promote the formation of cardiospheres. In some aspects, the cells are cultured in cardiosphere-growth medium comprising buffered media, amino acids, nutrients, serum or serum replacement, growth factors including but not limited to EGF and bFGF, cytokines including but not limited to cardiotrophin, and other cardiosphere promoting factors such as but not limited to thrombin. Cardiosphere-forming cells can be plated at an appropriate density necessary for cardiosphere formation, such as about 20,000-100,000 cells/mL. The cells can be cultured on sterile dishes coated with poly-D-lysine, or other natural or synthetic molecules that hinder the cells from attaching to the surface of the dish. Cardiospheres can appear spontaneously about 2-7 days or more after cardiosphere-forming cells are plated.

Q Cardiosphere-Derived Cells (CDCs)

CDCs are a population of cells generated by manipulating cardiospheres in the manner as described in, e.g., U.S. Patent Application Publication No. 2012/0315252, the disclosures of which are herein incorporated by reference in their entirety. For example, CDCs can be generated by plating cardiospheres on a solid surface which is coated with a substance which encourages adherence of cells to a solid surface of a culture vessel, e.g., fibronectin, a hydrogel, a polymer, laminin, serum, collagen, gelatin, or poly-D-lysine, and expanding same as an adherent monolayer culture. CDCs can be repeatedly passaged, e.g., passaged two times or more, according to standard cell culturing methods.

D) Exosomes

Exosomes are vesicles formed via a specific intracellular pathway involving multivesicular bodies or endosomal-related regions of the plasma membrane of a cell. Exosomes can range in size from approximately 20-150 nm in diameter. In some cases, they have a characteristic buoyant density of approximately 1.1-1.2 g/mL, and a characteristic lipid composition. Their lipid membrane is typically rich in cholesterol and contains sphingomyelin, ceramide, lipid rafts and exposed phosphatidylserine. Exosomes express certain marker proteins, such as integrins and cell adhesion molecules, but generally lack markers of lysosomes, mitochondria, or caveolae. In some embodiments, the exosomes contain cell-derived components, such as but not limited to, proteins, DNA and RNA (e.g., microRNA and noncoding RNA). In some embodiments, exosomes can be obtained from cells obtained from a source that is allogeneic, autologous, xenogeneic, or syngeneic with respect to the recipient of the exosomes.
Certain types of RNA, e.g., microRNA (miRNA), are known to be carried by exosomes. miRNAs function as post-transcriptional regulators, often through binding to complementary sequences on target messenger RNA transcripts (mRNAs), thereby resulting in translational repression, target mRNA degradation and/or gene silencing. For example, as described in WO 2014/028493, miR146a exhibits over a 250-fold increased expression in CDCs, and miR210 is upregulated approximately 30-fold, as compared to the exosomes isolated from normal human dermal fibroblasts.
Exosomes derived from cardiospheres and CDCs are described in, e.g., WO 2014/028493, the disclosures of which are herein incorporated by reference in their entirety. Methods for preparing exosomes can include the steps of: culturing cardiospheres or CDCs in conditioned media, isolating the cells from the conditioned media, purifying the exosome by, e.g., sequential centrifugation, and optionally, clarifying the exosomes on a density gradient, e.g., sucrose density gradient. In some instances, the isolated and purified exosomes are essentially free of non-exosome components, such as components of cardiospheres or CDCs. Exosomes can be resuspended in a buffer such as a sterile PBS buffer containing 0.01-1% human serum albumin. The exosomes may be frozen and stored for future use.
Exosomes can be prepared using a commercial kit such as, but not limited to the ExoSpin™ Exosome Purification Kit, Invitrogen® Total Exosome Purification Kit, PureExo® Exosome Isolation Kit, and ExoCap™ Exosome Isolation kit. Methods for isolating exosome from stem cells are found in, e.g., Tan et al, Journal of Extracellular Vesicles, 2:22614 (2013); Ono et al., Sci Signal, 7(332):ra63 (2014) and U.S. Application Publication Nos. 2012/0093885 and 2014/0004601. Methods for isolating exosome from cardiosphere-derived cells are found in, e.g., Ibrahim et al, Stem Cell Reports, 2:606-619 (2014). Collected exosomes can be concentrated and/or purified using methods known in the art. Specific methodologies include ultracentrifugation, density gradient, HPLC, adherence to substrate based on affinity, or filtration based on size exclusion.
For example, differential ultracentrifugation has become a leading technique wherein secreted exosomes are isolated from the supernatants of cultured cells. This approach allows for separation of exosomes from nonmembranous particles, by exploiting their relatively low buoyant density. Size exclusion allows for their separation from biochemically similar, but biophysically different microvesicles, which possess larger diameters of up to 1,000 nm.
Differences in flotation velocity further allows for separation of differentially sized exosomes. In general, exosome sizes will possess a diameter ranging from 30-200 nm, including sizes of 40-100 nm. Further purification may rely on specific properties of the particular exosomes of interest. This includes, e.g., use of immunoadsorption with a protein of interest to select specific vesicles with exoplasmic or outward orientations.
Among current methods, e.g., differential centrifugation, discontinuous density gradients, immunoaffinity, ultrafiltration and high performance liquid chromatography (HPLC), differential ultracentrifugation is the most commonly used for exosome isolation. This technique utilizes increasing centrifugal force from 2000×g to 10,000×g to separate the medium- and larger-sized particles and cell debris from the exosome pellet at 100,000×g. Centrifugation alone allows for significant separation/collection of exosomes from a conditioned medium, although it is insufficient to remove various protein aggregates, genetic materials, particulates from media and cell debris that are common contaminants. Enhanced specificity of exosome purification may deploy sequential centrifugation in combination with ultrafiltration, or equilibrium density gradient centrifugation in a sucrose density gradient, to provide for the greater purity of the exosome preparation (flotation density 1. 1-1.2 g/mL) or application of a discrete sugar cushion in preparation.
Importantly, ultrafiltration can be used to purify exosomes without compromising their biological activity. Membranes with different pore sizes—such as 100 kDa molecular weight cutoff (MWCO) and gel filtration to eliminate smaller particles—have been used to avoid the use of a nonneutral pH or non-physiological salt concentration. Currently available tangential flow filtration (TFF) systems are scalable (to >10,000 L), allowing one to not only purify, but concentrate the exosome fractions, and such approaches are less time consuming than differential centrifugation. HPLC can also be used to purify exosomes to homogeneously sized particles and preserve their biological activity as the preparation is maintained at a physiological pH and salt concentration.
Other chemical methods have exploit differential solubility of exosomes for precipitation techniques, addition to volume-excluding polymers (e.g., polyethylene glycols (PEGs)), possibly combined additional rounds of centrifugation or filtration. For example, a precipitation reagent, ExoQuick®, can be added to conditioned cell media to quickly and rapidly precipitate a population of exosomes, although re-suspension of pellets prepared via this technique may be difficult. Flow field-flow fractionation (F1FFF) is an elution-based technique that is used to separate and characterize macromolecules (e.g., proteins) and nano- to micro-sized particles (e.g., organelles and cells) and which has been successfully applied to fractionate exosomes from culture media.
Beyond these techniques relying on general biochemical and biophysical features, focused techniques may be applied to isolate specific exosomes of interest. This includes relying on antibody immunoaffinity to recognizing certain exosome-associated antigens. As described, exosomes further express the extracellular domain of membrane-bound receptors at the surface of the membrane. This presents a ripe opportunity for isolating and segregating exosomes in connections with their parental cellular origin, based on a shared antigenic profile. Conjugation to magnetic beads, chromatography matrices, plates or microfluidic devices allows isolating of specific exosome populations of interest as may be related to their production from a parent cell of interest or associated cellular regulatory state. Other affinity-capture methods use lectins which bind to specific saccharide residues on the exosome surface.

E) Examples

The present invention is further described with reference to the following non-limiting examples.

Example 1: CDC Culture

CDCs were prepared as described in U.S. Patent Application Publication No. 2012/0315252, the disclosures of which are herein incorporated by reference in their entirety.
In brief, heart biopsies were minced into small fragments and briefly digested with collagenase. Explants were then cultured on 20 mg/mL fibronectin-coated dishes. Stromal-like flat cells and phase-bright round cells grew out spontaneously from tissue fragments and reached confluency by 2-3 weeks. These cells were harvested using 0.25% trypsin and were cultured in suspension on 20 mg/mL poly-d-lysine to form self-aggregating cardiospheres. CDCs were obtained by plating and expanding the cardiospheres on a fibronectin-coated flask as an adherent monolayer culture. All cultures were maintained at 5% 02, 5% C02 at 37° C., using IMDM basic medium supplemented with 10% FBS, 1% penicillin/streptomycin, and 0.1 mL 2-mercaptoethanol. CDCs were grown to 100% confluency on a fibronectin-coated flask to passage 5.

Example 2: Isolation of Exosomes from CDCs

When the CDCs reached the desired confluency, the flask was washed three times with PBS. CDCs were treated with serum-free medium (IMDM) and were incubated at 37° C. at 5% 02, 5% C02 for 15 days. After 15 days, the conditioned medium was collected in 225 mL BD Falcon polypropylene conical tubes (BD 352075—Blue Top) and centrifuged at 2,000 rpm for 20 minutes at 4° C. to remove cells and debris (care was taken not to disturb the pellet). The conditioned medium was run through a 0.45 μπι membrane filter. The conditioned medium was concentrated using centrifugal filter. A 3 KDa Centricon Plus-70 Centrifugal Filter was pre-rinsed with 10-25 mL of molecular grade water and was centrifuged at 3220 g for five minutes at 18° C. Once the filter was rinsed, all remaining water was carefully removed without touching the filter. 15 mL of the conditioned medium was added to the filter and was centrifuged at 3220 g for 45 minutes at 18° C. After the initial spin, the remaining medium was mixed by pipetting and then spun again until the desired concentration was reached. The final sample was then run through a 0.22 μm syringe filter. 25 μL of the concentrated conditioned medium was diluted in 975 μL of PBS for particle count using the Nanosight. Another 100 μL of the concentrated conditioned medium was used to measure protein concentration. Protein was quantified using the DC protein Assay. In some cases, historical data was used to calculate the concentration of protein in the ultra-filtration by centrifugation (UFC) sample. The concentrated conditioned medium was used immediately or was stored at −80° C.

Example 3: Exosome Precipitation with 25% Polyethylene Glycol (PEG)

The appropriate volume of 25% PEG was added to the filtered concentrated conditioned medium. The samples were incubated at 4° C. for 12-16 hours on an orbital shaker. Once incubation was complete, the samples were centrifuged at 1500 g for 30 minutes at 4° C. The supernatant was carefully removed without disrupting the pellet. The pellet was resuspended in the desired volume of serum-free medium and sampled for particle count.

Example 4: CDC-EVs: 10 KDa & 1000 KDa Method: MSC-EVs: Newt-EVs

A) 10 KDa & 1000 KDa Method
CDC-EV (10 KDa or 1000 KDa) drug substance is obtained after filtering CDC conditioned medium (CM) containing EVs through a 10 KDa or 1000 KDa pore size filter. The final product, composed of secreted EVs and concentrated CM, is formulated in PlasmaLyte A and stored frozen.
B) MSC-EVs
Extracellular vesicles originating from human bone marrow mesenchymal stem cells (MSC-EVs) are obtained after filtering MSC CM containing EVs through a 10 KDa pore size filter following a similar process as for CDC-EV production. MSC-EVs are a non-cellular, filter sterilized product obtained from human MSCs cultured under defined, serum-free conditions. The final product, composed of secreted EVs and concentrated CM, is formulated in PlasmaLyte A and stored frozen. The frozen final product is “ready to use” for direct subconjunctival injection after thawing.
C) Newt-EVs
Extracellular vesicles originating from newt Al cell line (Newt-EVs) are obtained after filtering Al cell line CM containing EVs through a 10 KDa pore size filter following a similar process as for CDC-EV production. Newt-EVs are a non-cellular, filter sterilized product obtained from newt Al cells cultured under defined, serum-free conditions. The final product, composed of secreted EVs and concentrated CM, is formulated in PlasmaLyte A and stored frozen. The frozen final product is ready to use for direct subconjunctival injection after thawing.

Example 5: Test and Control Articles

The test article is a non-cellular, filter sterilized product obtained from human CDCs cultured under defined, serum-free conditions, prepared as exemplified in Examples 1-4. The general characteristics of the test article are summarized in Table 2.

TABLE 2

Characteristics	Description

Test article	CDC-EVs
Control article	PlasmaLyte A solution (Baxter)
Pharmaceutical form	CDC-EV suspension in PlasmaLyte for injection
Dosage/Strength	Low dose: 1.00 × 10⁹particles/200 μL
	(1×/week);
	High dose: 1.00 × 10¹⁰particles/200 μL
	(1×/week) for Days 21, 28 and 35, and
	switched to 3.33 × l0⁹particles/200 μL
	(2×/week) for Days 43, 47 and 50
Fill/Vial Size	0.4 mL per 2 mL vial
Product Container	CellSeal ® closed-system vial with needleless
	luer fittings
Storage Conditions	Frozen at −80° C.

Individual exosome vials were thawed at 4° C. or on ice. After each aliquot was completely thawed it was mixed gently (−6-8 times, avoiding excessive bubbling/foaming) using a micropipette, or an insulin/Hamilton type syringe with an integrated needle, prior to first administration.
The test and control articles were thawed for dosing overnight or on the day of dosing, and kept on wet ice throughout the dosing procedures.

Example 6: Systemic GVHD Animal Model; Study Design; Assessment of GVHD

Recipient BALB/c mice (n=45, male, 6-8 weeks of age) and donor C57BL/6 (n=30, male 6-10 weeks) were obtained from Charles River Laboratories (Wilmington, MA). Animals were acclimatized prior to study commencement. During this period, the animals were observed daily in order to reject any that presented in poor condition.
The study was performed in animal rooms provided with HEPA filtered air at a temperature of 70±5° F. and 50%±20% relative humidity. Animals were housed in groups of 15 per cage. Animal rooms were set to maintain a minimum of 12-15 air changes per hour. The room was on an automatic timer for a light/dark cycle of 12 hours on and 12 hours off with no twilight. Sterile Alpha-dri® bedding was used. Animals were fed with LabDiet 5053 sterile rodent diet and water was provided ad libitum.
FIGS. 1 and 5 illustrate how the animal model of systemic GVHD was generated, based on, e.g., Schroeder and DiPersio, “Mouse Models of Graft-Versus-Host Disease: Advances and Limitations,” Disease Models & Mechanisms, 4:318-333 (2011); van Leeuwen et al, “A Two-Phase Pathogenesis of Graft-Versus-Host Disease in Mice,” Bone Marrow Transplantation, 29: 151-158 (2002), with a few modifications. On Day −1, BALB/c mice were subjected to a single acute dose of 8 Gy of total body irradiation (TBI). On Day 0, the BALB/c recipients were given an intravenous injection, using a syringe with 30-gauge needle into the tail vein, of a combination of 2×10⁶splenocytes and T-cell depleted (CD3⁻) bone marrow cells 5×10⁶in sterile 1×PBS. Bone marrow (BM) and splenic cells (SC) were obtained from donor male C57BL/6 mice. The bone marrow cells were isolated using standard flushing practices and T-cell depleted using the cell surface T-cell antigen CD3, with a CD3-biotin kit from Miltenyi Biotec (130-093-021). Recipient animals were randomized into 3 groups of 15 animals each.
Following TBI on Day −1 up to Day 8, all animals were given supplemental high calorie highly palatable food in a dish on the bottom of the cage. Following transfer on Day 0, and then again as needed, all animals were given 1 mL/animal/day of supplemental fluids (warmed ringers solution) via subcutaneous injection. An additional 1 mL fluid may have been given in the afternoon on an as needed basis. Any animal exceeding −15% body weight loss was given highly palatable soft food and 1 mL supplemental fluids (warmed ringers solution) via subcutaneous injection.
Animals were dosed with the vehicle or the test article as detailed in Table 3 and as illustrated in FIG. 5 .

TABLE 3

			Cell
		TBI	transfer
Group	n	(Day −1)	(Day 0)	Treatment	Schedule	Sacrifice	Collections

1	15	8 Gy	5 × 10⁶ BM	PlasmaLyte				21, 28, 35, 43	Day 54	Plasma,
			and		and 50		liver, lung,
			2 × 10⁶SC		(I×/week)		eye, femur,
							colon
2	15	8 Gy	5 × 10⁶BM	Low dose:	21, 28, 35, 43	Day 54	Plasma,
			and	1.00 × 10⁹	and 50		liver, lung,
			2 × 10⁶SC	CDC-EVs	(I×/week)		eye, femur,
							colon
3	15	8 Gy	5 × 10⁶BM	High dose:	1.00 × 10¹⁰at	Day 54	Plasma,
			and	1.00 × 10¹⁰or	Days 21, 28 and		liver, lung,
			2 × 10⁶SC	3.33 × 10⁹	35 (I×/week),		eye, femur,
				CDC-EVs	and 3.33 × 10⁹at		colon
					Days

43, 47 and
					50 (2×/week)

Every day for the study period, each animal was weighed, and its survival was recorded in order to assess possible differences among treatment groups and as an indication for GVHD severity and/or possible toxicity resulting from the treatments. Any animal losing >30% of their starting weight was euthanized.
A clinical score for GVHD was obtained twice weekly for the entire study duration as assessed by a standard scoring system as detailed in Table 4, wherein the overall GVHD score was based on 5 criteria: percentage of weight change, posture (hunching) as exemplified in FIGS. 2A-C, activity, fur texture as exemplified in FIGS. 3 A-C, and skin integrity as exemplified in FIGS. 4A-C, with the maximum index=10.

TABLE 4

Criteria	Grade	0	Grade 1	Grade 2

Weight loss	<10%	>10%, <25%	>25%
Posture	Normal	Hunching noted only	Severe gait, impaired
		at rest	movement
Activity	Normal	Mild to moderately	Stationary until
		decreased	stimulated
Fur texture	Normal	Mild to moderate	Severe ruffling
		ruffling	and/or poor
			grooming
Skin	Normal	Scaling of paws	Obvious areas of
integrity		and/or tail	denuded skin

All animals were followed for at least 54 days. At the end of the study, all surviving animals were sacrificed by an overdose of CO2 and organs detailed in Table 4 were collected. Upon sacrifice, blood was collected by retro-orbital bleed into K2EDTA tubes. The blood was centrifuged and the plasma collected, flash frozen, and stored at −80° C. for further downstream analyses. Upon sacrifice, the liver was excised and the caudate lobe placed directly in formalin for 24 hours prior to transfer to 70% ethanol for long term storage. Upon sacrifice, the lungs and heart were removed en bloc, and the lungs were perfused with formalin through the heart right ventricle. The left (non-lobular) lung was removed and placed directly in formalin for 24 hours prior to transfer to 70% ethanol for long term storage.

Example 7: Outcome Evaluation & In-Life Monitoring

A) Statistical Analyses
Parametric data (weight change, engraftment) were evaluated using one-way ANOVA with Holm-Sidak's multiple comparison test to compare all groups to the vehicle control group. Non-parametric data (GVHD scores) were analyzed with Kruskal-Wallis with Dunn's post-hoc test. All statistical analyses were performed using GraphPad Prism 6.01 Software (La Jolla, CA). Statistical significance was achieved when p<0.05.
B) GVHD Score
As assessed using the multi-parameter GVHD scoring systems shown in Table 4 and as shown in FIG. 7A, intravenous injection of splenocytes and bone marrow cells induced GVHD in all animals. As shown in FIG. 7A, decreases in the overall GVHD score were observed in both groups dosed with CDC-EVs, and individual GVHD parameters (posture, activity, fur texture, skin integrity) are summarized in FIGS. 8A-D.
When an animal was forced to be euthanized because it had lost too much weight (>30% per IACUC protocol), the last observation was carried forward into subsequent data points to include the data for the dead animal.
Referring to FIG. 7B, the AUC was calculated to enable effective comparison of the groups by statistical test.
C) Body Weight Change
As shown in FIG. 6A, intravenous injection of splenocytes and bone marrow cells induced weight loss in all animals, and variable gains and losses were observed through the conclusion of the study. Following the initiation of dosing on Day 21, all animals continued to exhibit weight loss, peaking at around Day 33 followed by a partial recovery up until around Day 40. Animals dosed with either low dose or high dose of CDC-EVs continued to experience a general gain in weight up until the conclusion of the study on Day 54, whereas animals treated with the vehicle alone continued to lose weight. Indeed, the vehicle-treated animals had lost so much weight toward the end of the study that many of them were expected to die.
When an animal was forced to be euthanized because it had lost too much weight (>30% per IACUC protocol), the last observation was carried forward into subsequent data points to include the data for the dead animal.
Referring to FIG. 6B, the AUC was calculated to enable effective comparison of the groups by statistical test.
D) Survival
As shown in FIG. 9 , survival was tracked for all animals for the duration of the study and the percent survival was plotted, wherein treatment with both low dose and high dose CDC-EVs appeared to have beneficial effects on survival.
E) Bloody Stool & Diarrhea Incidence
The incidence of bloody stool and diarrhea was tracked for the entire duration of the study. There was no incidence of bloody stool at any point during the study (data not shown). As shown in FIGS. 10A-B, treatment with high dose CDC-EVs appeared to decrease the incidence of diarrhea, although no dramatic effect on diarrhea incidence was observed as a result of treatment with CDC-EVs.
F) Eye Inflammation
Immediately prior to sacrifice at Day 54, eye inflammation was assessed and scored, wherein a drop of 1% sodium fluorescein was applied to each eye, then the eye was rinsed off with saline, and viewed the fluorescence of the cornea with cobalt blue light under magnification. A masked/blinded observer assigned a score of 0 through 4 to each eye of each animal based on the degree of corneal fluorescein staining seen in the eye as follows: 0=no staining; 0.5=trace punctate staining: 1=punctate staining; 2=up to 25% staining of the corneal surface area; 3=up to 50% staining of the corneal surface area; 4=>50% corneal surface staining. The scores for each eye were averaged to achieve an “eye score” for each group. FIGS. 11 A-C show that while there was a trend toward lower eye score (therefore less corneal staining, a sign that there is reduced eye inflammation) in the CDC-EV-treated groups, with the high dose-treated animals performing even better.

Example 8: Histopathologic Examination

14 mouse colon samples and 14 mouse eyes from the animals of Groups 1-3 as described in Table 3 were processed routinely for histopathologic examination. One slide per block was sectioned and stained with hematoxylin and eosin (H&E) or microscopic analysis of tissue structure and inflammatory infiltrate. Glass slides were evaluated using light microscopy by a board-certified veterinary pathologist; colons were qualitatively evaluated and scored for inflammation, edema, mucosal erosion, and goblet cell depletion according to the histopathologic criteria listed in Tables 5-8. Each of the longitudinal sections on a given slide was scored. The mean score was calculated and reported for each parameter. Additionally, the mean sum score was calculated as the sum of inflammation, edema, mucosal necrosis, and goblet cell depletion.

TABLE 5

Inflammation
Score	Description


0	None present
1	Minimal change: Focal aggregate of a few cells of
	minimal diffuse inflammation
2	Mild change: Larger focal aggregates, multifocal
	small aggregates, or diffuse mild inflammation
3	Moderate change: Multifocal aggregates sometimes
	coalescing with one another or moderate diffuse
	change
4	Severe change: Marked diffuse inflammation

TABLE 6

Edema Score	Description

0	None present
1	Minimal change: Focal edema or minimal diffuse edema
2	Mild change: Larger focal areas of edema or diffuse
	mild edema
3	Moderate change: Multifocal areas of edema coalescing
	with one another or moderate diffuse edema
4	Severe change: Marked diffuse edema

TABLE 7

Mucosal Necrosis/
Epithelial Damage
Score	Description

0	None present
1	Minimal change: Focal epithelial necrosis
2	Mild change: Larger focal areas of necrosis or
	multifocal areas of necrosis
3	Moderate change: Multifocal necrosis coalescing
	into larger areas
4	Severe change: Areas of erosion through the
	mucosa to the submucosa

TABLE 8

Goblet Cell
Depletion Score	Description

0	None present
1	Minimal change: Focal goblet cell loss in one
	or a few colonic glands
2	Mild change: Larger focal areas of goblet cell
	loss, or multifocal goblet cell loss in several
	glands

3	Moderate change: Multifocal to regionally
	extensive goblet cell loss
4	Severe change: Marked diffuse goblet cell loss

Scores for each feature were summed to obtain a sum colitis score (range 0-16). Colonic histologic lesions not addressed in this grading scheme and lesions in eye sections were scored semi-quantitatively 0-5, where 0=not present, 1=minimal, 2=mild, 3=moderate, 4=marked, 5=severe. See, e.g., Crissman et al, “Best Practices Guideline: Toxicologic Pathology,” Toxicol Pathol, 32: 126-31 (2004).
A) Colon
Expected histologic lesions of GVHD colitis in mice included primarily mononuclear inflammation in the colonic mucosa; expansion of the submucosa and lymphatic vessels by edema; epithelial damage or mucosal necrosis, with or without erosion and infiltration of neutrophils; and depletion of goblet cells. See, e.g., Eigenbrodt et al, “Histologic Similarity of Murine Colonic Graft-versus-host Disease (GVHD) to Human Colonic GVHD and Inflammatory Bowel Disease,” Am J Pathol, 137: 1065-76 (1990). Additional expected lesions included lymphocytic satellitosis, the infiltration of lymphocytes into the colonic gland with epithelial cell apoptosis; epithelial hyperplasia, characterized by gland elongation, basophilia and increased mitotic figures; and mesenteric adipose necrosis with subacute inflammation, the infiltration of neutrophils, macrophages and fewer lymphocytes and plasma cells into the mesentery adjacent the colon.
As shown in FIGS. 12-13 , decreases in mucosal necrosis and goblet cell depletion scores in the test article-low dose group (Group 2) translated into a reduction in sum score compared to the untreated group (Group 1).
B) Eye
Expected histologic lesions in eyes from mice with GVHD included lymphocytic satellitosis, characterized by infiltration of low numbers of lymphocytes into the corneal epithelium, with concurrent epithelial cell vacuolization and/or apoptosis; corneal epithelial necrosis with progression to ulceration was present in one sample. See, e.g., Perez et al, “Limbus Damage in Ocular Graft-versus-Host-Disease,” Biol Blood Marrow Transplant, 17: 270-273 (2011). Corneal subacute inflammation was characterized by infiltration of neutrophils, lymphocytes or histiocytes into the corneal stroma and/or epithelium, accompanied by stromal edema or occasional foci of stromal necrosis. Neovascularization was characterized by ingrowth of blood vessels into the corneal stroma. Subacute inflammation was also observed in the limbus, conjunctiva (when present) and the anterior uveal tract, including the iris or anterior chamber. Mineralization was visible in the corneal stroma or in the immediate sub-basilar zone of the corneal epithelium (subepithelial). Lens fiber degeneration (cataract formation), characterized by posterior migration and disorganization of the lens epithelium and bladder cell formation, was observed as well.
As shown in FIG. 15 , lymphocytic satellitosis, corneal and anterior uveal subacute inflammation and neovascularization scores were most severe in Group 1 (untreated); with lower scores or complete absence of these lesions in the test article-treated animals (Groups 2 and 3).

Example 9: CDC-Derived Extracellular Vesicles (CDC-EVs) Interaction with T Cells

The purpose of this study was to determine the immunological activity of CDC-EVs linked to T cells regulation.

Characterization of CDC-EVs & Immune Phenotype

For FIG. 16 , the expression of exosome informative markers was analyzed by CDC-EVs using Western blotting. CDC-EVs (20 μl=10 μg) were lysed using RIP A buffer and loaded to 10% SDS-Page gels then transferred to nitrocellulose membrane. Membranes were blocked with 5% BSA then hybridized with specific antibodies against HSP70, CD81, CD63, ALIX, HLA II and p-actin. CDCs and dendritic cells (DC) lysates as well as exosome-free supernatant (SN) were used as controls. CDC-EVs expressed expected exosome markers CD81, CD63 and ALIX while SN was completely negative.
CDC-EVs were next analyzed for the surface expression of immune relevant markers. CDC-EVs (30 μl=15 μg) have been coupled to 5 μl Latex beads (4 μπι). CDC-EVs/beads were treated successively with 100 mM glycine and 2% BSA buffers in order to block any eventual non-specific binding of these EVs eads with antibodies or with beads. After washing, EVs/beads were stained with specific antibodies against relevant immune molecules acquired on Canto II BD Facs and analyzed by FlowJo software. Beads incubated with the same amount of respective antibodies were used as a control.
Compared to beads-antibody control, CDC-EVs expressed HLA class I molecules and CD86, but were negative for HLA II and CD80 molecules. CDC-EVs seem to express the co-stimulatory PD-L1 molecule but not the ICOS-L. NK activating receptor ligands were remarkably expressed on the CDC-EVs. For FIG. 17 , significant expression of both EVs markers CD81 and CD63 was detected.

Indirect T Cells Activation and Proliferation in Response to Allogeneic EVs

Monocytes were isolated from blood samples obtained from two different healthy donors. Isolated-monocytes were then stimulated for 6 days with a combination of GM-CSF (20 ng/ml) and IL4 (20 ng/ml) to allow their differentiation to DC. Differentiation of monocytes with GM-CSF+IL4 generates immature DC (iDC) marked by moderate expression of HLA II, CD80, and CD86 molecules, absence of CD 16 (marker of monocytes/macrophages), and low expression of TLR-2. These monocyte-derived iDC were then incubated for an overnight with HLA-mismatched CDC-EVs.
iDC cultured with EVs displayed features of mature DC (mDC); they up-regulated their HLA II, CD80 and CD86 molecules, which is recognized as mDC properties, as shown in FIG. 28 . Then 1×10⁴of iDCs or iDCs that were in contact with EVs (iDC-EVs) were co-cultured with autologous T cells (1×10⁵) in U-bottom 96 wells plates for another 6 days. Autologous T cells co-cultured with iDC or iDC-EVs where analyzed for their expression of CD69 and HLA-DR, and for their proliferation. Although the response of T cells from two different donors was variable, as a whole iDC-EV were more potent in activating and inducing the proliferation of T cells than iDCs alone, as shown in FIG. 29 .
Compared to direct CDC-EV-induced T cells proliferation, the magnitude of indirect CDC-EV-induced T cells proliferation is fairly higher.
The capacity of CDC-EVs to stimulate T cells when presented by mature DC (mDC) was evaluated. Given that mDC have very low phagocytic activity and to insure appropriate uptake of EVs and based on previous experience of phagocytizing apoptotic bodies, the maturation of DC was induced by treating iDC and iDC-EVs for an overnight with IFNγ (500 IU/ml), which is a recognized inducer of DC maturation. Compared to iDC, these mDC showed higher expression of HLA II, CD80 and CD86, and higher expression of TLR-2, which are the know features of mDC. The presence of CDC-EVs during iDC maturation to mDC further up-regulated HLA II, CD86, CD80, and TLR-2 molecules, as shown in FIG. 30 .
mDC or mDC-EVs were then co-cultured with autologous T cells (1×10⁵) in U-bottom 96-wells plates or 6 days and their activation (expression of CD69 and HLA-DR) and proliferation was analyzed.
Again, the responses from two donors, were variable but as a whole mDC-EVs were more potent in activating and inducing the proliferation of T cells than mDCs alone. Compared to iDC-EVs-induced response, mDC-EV-induced T cell activation and proliferation for the same donor was higher.
The ensemble of our results in regard of T cells activation and proliferation suggest that CDC-EVs can activate and induce the proliferation of T cells mainly through the indirect pathway without rolling out the direct pathway since we did observe weak direct activation.

In Vitro Uptake of CDC-EVs by T-Cells

The ability of T cells for CDC-EVs uptake was evaluated in vitro. Human CDC-EVs were fluorescently labeled using the membrane dye DiD and were added to Jurkat T cells (Jurkat, Clone E6-; ATTC® TIN-152™). Uptake was measured by flow cytometry 1 hour, 4 hours, or overnight after addition of EVs. Jurkat T cells tested positive for DmiD fluorescence at the different times tested, indicating that they uptake CDC-EVs (FIG. 18 ).

Immune-Modulation by CDC-EVs

The capacity of CDC-EVs to modulate an ongoing immune response in an allogeneic setting was then investigated. To this end, HLA-mismatched unfractionated CFSE-labeled PBMC (1×10⁵) were stimulated with PHA (1 μg/ml) in the absence or presence of various doses of CDC-EVs as shown in FIG. 19 (upper panel) in U-bottom 96 well plates and allogeneic T cells proliferation was evaluated by monitoring CFSE. CDC-EVs were able to down regulate PHA-induced CD4+ and CD8+ T cell proliferation. CDC-EVs-induced down regulation of T cells proliferation was dose dependent, and at the highest used dose (20×10⁹particles) CDC-EVs were more potent in down regulating ongoing response than their parental cells, as shown in FIG. 19 .
CDC-EV-induced immune modulation is likely through direct effects since similar results were obtained when purified CD3+ T cells were used instead of PBMC within the same experimental settings. Indeed, CDC-EVs were able to down regulate PHA-induced expression of CDC69 and/or HLA-DR on T cells obtained from 2 different donors, as shown in FIG. 20 .
For FIG. 21 , down-modulation of T cells activation markers by CDC-EVs resulted in a pronounced down regulation of PHA-induced CD4+ and CD8+ T cell proliferation.
For FIG. 22 , despite inter-donor variability and within the limit of results obtained with two donors only, CDC-EVs are potent immune modulators.
These studies of capacity of CDC-EVs to induce immune-modulation demonstrated that they are potent immune-modulators.

Claims

1. A method of modulating T cells, the method comprising contacting T cells with an effective amount of extracellular vesicles derived from cardiosphere-derived cells (CDCs).

2. The method of claim 1, wherein proliferation of said contacted T cells is down regulated.

3. The method of claim 1, wherein expression of CDC69 is down regulated in said contacted T cells.

4. The method of claim 1, wherein expression of HLA-DR is down regulated in said contacted T cells.

5. The method of claim 1, wherein expression of CDC69 and expression of HLA-DR are down regulated in said contacted T cells.

6. The method of claim 1, wherein the T cells comprise CD3+ T cells.

7. The method of claim 1, wherein the T cells comprise CD4+ or CD8+ T cells.

8. The method of claim 1, wherein the extracellular vesicles express HLA class I molecules and do not express HLA II molecules.

9. The method of claim 1, wherein the extracellular vesicles express CD86 and do not express CD80.

10. The method of claim 1, wherein the extracellular vesicles express HLA class I and CD86 molecules and do not express HLA II and CD80 molecules.

11. The method of claim 1, wherein the extracellular vesicles express PD-LI and do not express ICOS-L.

12. The method of claim 1, wherein the extracellular vesicles express NK activating receptor ligands.

13. The method of claim 1, wherein the extracellular vesicles express NK activating receptor ligands, PD-L1, CD86, and HLA class I molecules.

14. The method of claim 13, wherein the extracellular vesicles do not express CD80, ICOS-L, and HLA II molecules.

15. The method of claim 1, wherein the effective amount of the extracellular vesicles is 5×10⁹to 20×10⁹extracellular vesicle particles.

16. The method of claim 1, wherein the T cells are in vivo and said contacting comprises administering said effective amount of extracellular vesicles to a subject.

17. The method of claim 16, wherein the subject had received hematopoietic stem cell transplant (HSCT).

18. The method of claim 17, wherein said effective amount of extracellular vesicles is administered one or more times after the subject had undergone HSCT.

19. The method according to claim 17, wherein said effective amount of extracellular vesicles is administered 1, 2, 3, 4, 5, 6, 7, or 8 weeks after HSCT.

20. The method according to claim 17, wherein said effective amount of extracellular vesicles is administered in multiple administrations made 7 days apart between successive administrations.